Induction of proliferation by 15-deoxy-Δ12,14- prostaglandin J2 and the precursors in monocytic leukemia U937

Pharmacology

Volumn 71, Issue 4, 2004, Pages 181-191

  Azuma, Yasutaka ^a   Watanabe, Kyoko ^a   Date, Masataka ^a   Daito, Michiharu ^a   Ohura, Kiyoshi ^a  

^a OSAKA DENTAL UNIVERSITY   (Japan)

Author keywords

15dPGJ2; Cell cycle; Leukemia; p38 MAPK; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; CIGLITAZONE; DELTA12 PROSTAGLANDIN J2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN D2; PROSTAGLANDIN J2; PROTEIN P18; PROTEIN P27;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL DIVISION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTAGLANDIN D2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 4043082707     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078084     Document Type: Article

References (34)

1. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803-812.
2. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995;83:813-819.
3. Kliewer SA, Sundseth SS, Jones SA, Browns PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Wilson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor α and γ. Proc Natl Acad Sci USA 1997;94:4318-4323.
4. Sato H, Ishikawa S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi M, Fukuda R, Nagasue N, Kinoshita Y: Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 2000;83:1394-1400.
5. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-405.
6. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M, Mulshine JL: Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 2001;15:2007-2009.
7. Yang WL, Frucht H: Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001;22:1379-1383.
8. Eibl G, Wente MN, Reber, HA, Hines OJ: Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 2001;287:522-529.
9. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD: Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer, and its role in inducing cell death. Neoplasia 1999;1:330-339.
10. Gastri-Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPARγ inhibits cell growth, and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-139.
11. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T: Ligands for peroxisome proliferatoractivated receptor-γ inhibit growth, and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-2177.
12. 2 but not troglitazone. J Dent Res 2003;82:802-806.
13. 2 is a negative regulator of macrophage functions. Int Immunopharmacol 2001;1:2101-2108.
14. 2 inhibits IL-10 and IL-12 production by macrophages. Biochem Biophys Res Commun 2001;283:344-346.
15. Azuma Y, Ohura K: Alteration of constitutive apoptosis in neutrophils by quinolones. Inflammation 2003;27:123-130.
16. Azuma Y, Ohura K: Endomorphin-2 modulates productions of TNF-α, IL-1β, IL-10 and IL-12, and alters functions related to innate immune of macrophages. Inflammation 2002;26:223-232.
17. Azuma Y, Ohura K, Wang PL, Shinohara M: Endomorphins delay constitutive apoptosis and alter the innate host defense functions of neutrophils. Immunol Lett 2002;81:31-40.
18. Buchdunger E, O'Reilly T, Wood J: Pharmacology of imatinib (STI571). Eur J Cancer 2002;38:S28-S36.
19. Utsugi M, Dobashi K, Koga Y, Masubuchi K, Shimizu Y, Endou K, Nakazawa T, Mori M: Ambroxol inhibits platelet-derived growth factor production in human monocytic cells. Eur J Pharmacol 2002;436:47-51.
20. 2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 1999;59:2739-2746.
21. 2 induce diverse biological response via PPARγ activation in cancer cells. Prostaglandins Other Lipid Mediat 2000;62:23-32.
22. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain peroxisome proliferator-activated receptor γ (PPARγ): Differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23.
23. 2 induces apoptosis of human hepatic myofibroblasts. J Biol Chem 2001;276:38152-38158.
24. 2 derivatives really playing the part? Cell Signal 2002;14:573-583.
25. Han S, Sidell N: Peroxisome proliferator-activated receptor-γ- independent induction of CD36 in THP-1 monocytes by retinoic acid. Immunology 2002;106:53-59.
26. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygenated species. J Biol Chem 2002;33:29681-29685.
27. Nerve RN, Holbro T, Hynes NE: District roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002;21:4567-4576.
28. Wang S, Nath N, Minden A, Chellappan S: Regulation of Rb and E2F by signal transduction cascades: Divergent effects of JNK1 and p38 kinases. EMBO J 1999;18:1559-1570.
29. Hou ST, Xie X, Baggley A, Park DS, Chen G, Walker T: Activation of the Rb/E2F1 pathway by the nonproliferative p38 MAPK during FAS (APO1/CD95)-mediated neuronal apoptosis. J Biol Chem 2002;277:48764-48770.
30. 2 checkpoint. Oncogene 2002;21;8089-8104.
31. Cip1 by phosphorylation. J Biol Chem 2002;277:29792-29802.
32. Kim JY, Choi JA, Kim TH, Yoo YD, Kim JI, Lee YJ, Yoo SY, Cho CK, Lee YS, Lee SJ: Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J Cell Physiol 2002;190:29-37.
33. MAPK pathway. J Biol Chem 1996;271:20608-20616.
34. Page K, Li J, Hershenson MB: p38 MAP kinase negatively regulates cyclin D1 expression in airway smooth muscle cells. Am J Physiol 2001;280:L955-L964.